Abstract: Methods for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample. The methods include the steps of: (a) contacting the biological sample with a PERV-B.RBD ligand, a variant and/or a fragment thereof; and, detecting and/or measuring the binding of the PERV-B.RBD ligand, variant and/or fragment thereof to SMVT.

Abstract: A circularly polarized radiating element includes at least one excitation aperture for a wave that is linearly polarized with what is referred to as an excitation first polarization, a frequency selective surface and a metasurface comprising a two-dimensional and periodic array of metasurface cells, the excitation aperture opening onto the metasurface, the metasurface cells all being oriented identically with respect to the excitation polarization and configured to: reflect an incident wave having the excitation polarization in order to form a reflected wave polarized with the excitation polarization, and depolarize and reflect the incident wave in order to form a reflected wave polarized with the orthogonal polarization, having a phase difference substantially equal to ±90° with respect to the reflected wave polarized with the excitation polarization, and having an amplitude substantially equal to the amplitude of a wave radiated by the frequency selective surface, generated from the reflected wave polarized

Abstract: A process for fabricating a heterostructure made of semiconductor materials having a crystalline structure of wurtzite type, includes the following steps: structuring a surface of a zinc oxide monocrystalline substrate into mesas; depositing by epitaxy at least one layer of semiconductor materials having a crystalline structure of wurtzite type, forming the heterostructure, on top of the structured surface. Heterostructure obtained by such a process. A process for fabricating at least one electronic or optoelectronic device from such a heterostructure is also provided.

Abstract: A computer-implemented method for identifying mechanical parameters of an object subjected to mechanical stress is provided. The method comprises a step of acquiring, by an imaging means, images of the object taken before and during the application of the mechanical stress, three steps of calculating the effects due to the stress carried out either on the basis of the modeling of the recorded images or on the basis of a theoretical mechanical modeling of the stress, a step of defining a functional equal to the difference between the two models and a last step of minimizing said functional so that the experimental model is as close as possible to the theoretical mechanical model. Additional measurements make it possible to refine the method.

Abstract: A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD32 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD32a differentiation marker are absent.

Abstract: An active laser medium for emitting a light beam by laser effect includes an X—F2-doped crystal, wherein X is a chemical element from the alkaline-earth family and F is fluorine. The crystal is doped with trivalent ions including: a first category of optically active dopant ions, in which each dopant ion is an ion of a first rare earth; and a second category of optically inactive dopant ions, referred to as buffer ions, in which each dopant ion is an ion of a rare earth different from the first rare earth. The second category of dopant ions has at least ions of a second rare earth and ions of a third rare earth, different from one another. The invention provides an active laser medium that can be used to obtain both a desired emission spectrum shape and a high thermal conductivity.

Abstract: The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.

Abstract: A composition for the adhesion of biological tissues to one another, for the adhesion of a material to a biological tissue, for the adhesion of an adhesive or of a substance to the surface of a biological tissue, for blocking an orifice in a biological tissue, for reinforcing a biological tissue and/or for fixing and stabilising a biological tissue. A monomer that is polymerisable under the effect of ultraviolet (UV) radiation and in that the viscosity of said composition is less than 10 mPa·s at 20° C.

Abstract: A method for determining a flow rate and/or a concentration of particles of a fluid flowing in a chamber, which includes the steps of: producing an ultrasound beam of a given frequency with a first transducer such that all fluid components traveling through an intersection region between the ultrasound beam and the chamber are insonated by the first transducer; receiving Doppler-shifted ultrasound signals generated by the fluid components in the insonated region of the chamber with a second transducer; acquiring the ultrasound signals received by the second transducer during an acquisition time; obtaining a Doppler Power Spectrum of the acquired ultrasound signals; and determining the flow rate and/or the concentration of particles of the fluid by adjustment between, on the one hand, the obtained Doppler Power Spectrum and, on the other hand, a model of the Doppler Power Spectrum.

Abstract: Disclosed are new precursors of recyclable cross-linked diene elastomers including chain-end units with furanyl groups, their use in the preparation of the recyclable elastomers and their process of preparation. Also disclosed are new recyclable cross-linked diene elastomers, their preparation process and their uses.

Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.

Abstract: Disclosed is a method for the culture of photosynthetic organisms selected from among microalgae, cyanobacteria and macroalgae using a continuous or discontinuous CO2 source.

Abstract: The invention relates to a method for labeling specifically living bacteria, comprising the steps of: a) incubating said bacteria of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into the envelope of such bacteria, and b) contacting said modified monosaccharide residue incorporated within the envelope of the bacteria with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group with said second reactive group, characterized in that said modified monosaccharide compound has the following formula (I), or a salt thereof: Wherein —A, B and C can be independently H, OH, NH2, OH and NH2 being substituted or not by protecting groups thereof and —D is an alkyl chain in C2 to C4, each carbon being substituted or not by OH or NH2, OH and NH2 being substituted or not b

Abstract: The present invention relates to a method for ex vivo generating and expanding ?? Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR?? unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR?? unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR??+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo ?? Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR??+ Foxp3+.

Abstract: The present disclosure relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.

Abstract: A method for controlling the operation of a robot within a system. The system includes the robot and sensors to analyze the concentric environment of the system. The sensors include a contact sensor, a proximity sensor and a vision and location sensor. For each of the axes of the robot, a maximum allowable force value is obtained. If the force on one of the axes of the robot is greater than the maximum value, the robot is stopped in its position. A concentric monitoring space or a security space is obtained as a function of the speed of the robot. The environment of the robot is monitored by the sensors. If the intrusion of an object is detected in the safe space of the robot, the maneuvering speed of the robot is gradually decreased to a safe speed. The process is repeated for the next axis of the robot.

Abstract: The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

Abstract: The invention relates to a process for preparing a dichromatic material, in the form of a translucent film, comprising monodisperse nanoparticles formed of gold and optionally of a noble metal chosen from platinum, palladium, silver and copper, and at least one organic macromolecule chosen from proteins, polysaccharides and synthetic polymers; said dichromatic material; and the uses thereof.

Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the model in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.

Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.